Bay Capital Advisors LLC Invests $231,000 in Astrazeneca Plc $AZN

Bay Capital Advisors LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,512 shares of the company’s stock, valued at approximately $231,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Triumph Capital Management purchased a new stake in Astrazeneca during the 3rd quarter worth approximately $25,000. Bangor Savings Bank lifted its position in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Rakuten Investment Management Inc. purchased a new position in shares of Astrazeneca in the third quarter valued at approximately $31,000. JPL Wealth Management LLC acquired a new stake in shares of Astrazeneca in the third quarter worth approximately $35,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in shares of Astrazeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Trading Up 1.9%

Shares of Astrazeneca stock opened at $200.98 on Thursday. The company has a market cap of $311.70 billion, a P/E ratio of 30.68, a P/E/G ratio of 1.49 and a beta of 0.35. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a one year low of $122.48 and a one year high of $212.71.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were issued a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is currently 66.26%.

Analyst Ratings Changes

Several research analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Weiss Ratings began coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Guggenheim reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.